Effects of ticlopidine or ticlopidine plus aspirin on platelet aggregation and ATP release in normal volunteers: Why aspirin improves ticlopidine antiplatelet activity

Clinical and Applied Thrombosis/Hemostasis

Volumn 5, Issue 4, 1999, Pages 243-246

  Altman, Raul ^a   Scazziota, Alejandra ^a   Rouvier, Jorge ^a   Gonzalez, Claudio ^a  

^a Centro de Trombosis de Buenos Aires   (Argentina)

Author keywords

Antiplatelet treatment; Antithrombotic therapy; Aspirin; Ticlopidine

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ARACHIDONIC ACID; CLOPIDOGREL; TICLOPIDINE;

ADULT; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; DRUG EFFECT; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA;

EID: 0032706553     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602969900500407     Document Type: Article

References (21)

1. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330:1287.
2. Roth GJ, Calverley DC. Aspirin, platelets, and thrombosis: theory and practice. Blood 1994;83:885.
3. Schör K. The basic pharmacology of ticlopidine and clopidogrel. Platelets 1993;4:252.
4. CAPRIE Steering Committee. A randomized, blinded, trial of clapidogrel versus aspirin in patients at risk of ischaemic event. (CAPRIE), Lancet 1996;348:1329.
5. Hass WK, Easton JD, Adams HP Jr, et al., for the Ticlopidogrel Aspirin Stroke Study Group. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke high-risk patients. N Engl J Med 1989;321:501.
6. Haal P, Nakamura S, Maiello L, et al. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular sound-guided stent implantation. Circulation 1996:93:215.
7. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting Stent anticoagulation restenosis study investigators. N Engl J Med 1998;339:1665.
8. Gregorini L, Marco J, Fajadet J, et al. Ticlopidine and aspirin pretreatment reduces coagulation and platelet activation during coronary dilation procedures. J Am Coll Cardiol 1997;29:13.
9. Altman R, Scazziota A. Synergistic activity of paf-acether and sodium arachidonate in human platelet aggregation. 2. Unexpected results after aspirin intake. Thromb Res 1986;43:113.
10. Altman R, Scazziota A, Cordero Funes J. Why single dose of aspirin may not prevent platelet aggregation. Thromb Res 1988; 51:259.
11. Willerson JT. Inhibition of platelet glycoprotein IIb/IIIa receptors will they be useful when given chronically? Circulation 1996;94: 866.
12. Willerson JT. Stent restenosis. Can effective antithrombotic therapy be protective? Circulation 1997;96:383.
13. Szczeklik A, Musial J, Undas A, et al. Inhibition of thrombu generation by aspirin is blunted in hypercholesterolemia. Arterio scler Thromb Vasc Biol 1996;16:948.
14. Maalej N, Folts JD. Increased shear stress overcomes the anti thrombotic platelet inhibitory effect of aspirin in stenosed dog coronary arteries. Circulation 1996;93:1201.
15. Santos MT, Valles J, Aznar J, et al. Prothrombotic effects of eryth rocytes on platelet reactivity. Reduction by aspirin. Circulation 1997;95:63.
16. Altman R, Scazziota A. Why aspirin cannot prevent arterial thromb bosis [Letter]. Circulation 1996;94:3002.
17. Lecompte TP, Lecrubier C, Bouloux C, et al. Antiplatelet effects of the addition of acetylsalicylic acid 40 mg daily to ticlopidine in human healthy volunteers. Clin Appl Thromb Hemost 1997;3:245
18. Rupprecht HJ, Darius H, Borkowski U, et al. Comparison of an tiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation. Circulation 1998;97:1046.
19. Zucker ML, Budd SE, Dollar LE, et al. Effect of diltiazem and low-dose aspirin on platelet aggregation and ATP release induced by paired agonists. Thromb Haemost 1993;70:332.
20. Byrne A, Moran A, Maher M, et al. Continued thromboxane A2 formation despite administration of a platelet glycoprotein IIb/IIIa in patients undergoing coronary angioplasty. Arterioscler Thromb Vasc Biol 1997;17:3224.
21. Catella-Lawson F, FitzGerald GA. Confusion in reperfusion. Problems in the clinical development of antithrombotic drugs [Editorial]. Circulation 1997;95:793.